134 related articles for article (PubMed ID: 28654428)
1. Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients.
Cheng E; Ko D; Nguyen M; Moo TA; Andreopoulou E; Hoda SA; D'Alfonso TM
Am J Surg Pathol; 2017 Sep; 41(9):1275-1282. PubMed ID: 28654428
[TBL] [Abstract][Full Text] [Related]
2. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
Rabban JT; Glidden D; Kwan ML; Chen YY
Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
[TBL] [Abstract][Full Text] [Related]
3. A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy.
Morohashi S; Yoshizawa T; Seino H; Hirai H; Haga T; Ota R; Wu Y; Yoshida E; Hakamada K; Kijima H
Oncol Rep; 2016 May; 35(5):2592-8. PubMed ID: 26935647
[TBL] [Abstract][Full Text] [Related]
4. Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy: A Rare Pattern of Residual Breast Carcinoma.
Guilbert MC; Overmoyer B; Lester SC
Am J Surg Pathol; 2018 May; 42(5):679-686. PubMed ID: 29394169
[TBL] [Abstract][Full Text] [Related]
5. Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response.
Lee H; Jang Y; Cho YA; Cho EY
Hum Pathol; 2024 Mar; 145():1-8. PubMed ID: 38311186
[TBL] [Abstract][Full Text] [Related]
6. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
7. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
8. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy.
Beek MA; Tetteroo E; Luiten EJ; Gobardhan PD; Rutten HJ; Heijns JB; Voogd AC; Klompenhouwer EG
Eur J Surg Oncol; 2016 May; 42(5):672-8. PubMed ID: 26898838
[TBL] [Abstract][Full Text] [Related]
10. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
[TBL] [Abstract][Full Text] [Related]
11. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
[TBL] [Abstract][Full Text] [Related]
12. Postneoadjuvant Pure and Predominantly Pure Intralymphatic Breast Carcinoma: Case Series and Literature Review.
MacColl CE; Paré G; Salehi A; Hodgson N; Williams P
Am J Surg Pathol; 2021 Apr; 45(4):537-542. PubMed ID: 33105157
[TBL] [Abstract][Full Text] [Related]
13. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
15. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
Javid S; Segara D; Lotfi P; Raza S; Golshan M
Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
[TBL] [Abstract][Full Text] [Related]
17. [Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer].
Tokita H; Aruga T; Yamashita T; Saji S; Suzuki E; Horiguchi K; Kitagawa D; Sekine S; Horiguchi S; Hirashima Y; Kuroi K
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1639-45. PubMed ID: 21996959
[TBL] [Abstract][Full Text] [Related]
18. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
[TBL] [Abstract][Full Text] [Related]
19. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
